Andrew Jacobs's profile photo

Andrew Jacobs

New York

Health and Science Reporter at The New York Times

Andrew Jacobs is a reporter with the Science desk of The New York Times covering global health. Formerly in Beijing, Brazil and other far-flung locales.

Featured in: Favicon nytimes.com Favicon msn.com Favicon indiatimes.com (+2) Favicon independent.co.uk Favicon yahoo.com (+2) Favicon cnbc.com Favicon smh.com.au Favicon asahi.com Favicon boston.com Favicon chicagotribune.com

Articles

  • 2 weeks ago | flipboard.com | Andrew Jacobs

  • 3 weeks ago | nytimes.com | Andrew Jacobs

    The few domestic companies that still make protective gear for health care workers have clamored for federal intervention. But they worry President Trump's trade war with China won't help. Few domestic industries have been as devastated by the flood of cheap Chinese imports as manufacturers of face masks, exam gloves and other disposable medical gear that protects health care workers from infectious pathogens.

  • 1 month ago | thestar.com.my | Andrew Jacobs |Emily Anthes

    WOULD you try a chicken sandwich made from lab-grown meat? If so, don’t expect to find one in Mississippi anytime soon, because the southern US state has moved to ban so-called cultivated or cell-derived meat, joining a growing list of states seeking to outlaw the emerging food technology.

  • 2 months ago | nytimes.com | Andrew Jacobs |Emily Anthes

    The proposed ban, unanimously passed by the House of Representatives, carries a $500 fine and up to three months in jail for anyone growing or selling such products within the state. The bill, which Gov. Tate Reeves of Mississippi, a Republican, is expected to sign, is the latest in a series of legal maneuvers by states seeking to constrain the nascent cell-cultured meat industry - despite the fact that such products are currently unavailable to consumers in the United States.

  • Feb 4, 2025 | nytimes.com | Andrew Jacobs |Rachel Nuwer

    After more than three decades of planning and a $250 million investment, Lykos Therapeutics' application for the first psychedelic drug to reach federal regulators was expected to be a shoo-in.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
17K
Tweets
1K
DMs Open
Yes
Andrew Jacobs
Andrew Jacobs @AndrewJacobsNYT
10 Aug 24

A significant setback for psychedelic medicine: F.D.A. Declines to Approve MDMA Therapy, Seeking More Study https://t.co/FxrtSG2T4Z

Andrew Jacobs
Andrew Jacobs @AndrewJacobsNYT
8 Aug 24

Veterans and Lawmakers Lobby in Bipartisan Push for MDMA Therapy https://t.co/gt8wkSmmme

Andrew Jacobs
Andrew Jacobs @AndrewJacobsNYT
5 Mar 24

After decades in the shadows, a powerful psychedelic is drawing fresh attention for its potential to treat opioid addiction and other health issues. https://t.co/x6HNhflJUK